Adepitan A Owosho1, Shih-Chiang Huang2, Sonja Chen2, Shruti Kashikar1, Cherry L Estilo1, Suzanne L Wolden3, Leonard H Wexler4, Joseph M Huryn1, Cristina R Antonescu5. 1. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, United States. 2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States. 3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, United States. 4. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, United States. 5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States. Electronic address: antonesc@mskcc.org.
Abstract
BACKGROUND: Based on their distinctive histologic and genetic features, the latest WHO classification of soft tissue tumors includes four pathologic variants of rhabdomyosarcoma (RMS): embryonal (ERMS), alveolar (ARMS), spindle cell-sclerosing (SRMS-ScRMS) and pleomorphic RMS. The aim of this study focused on a detailed clinicopathologic and survival analysis of head and neck RMS (HNRMS) using the latest pathologic and molecular criteria reflecting this new subclassification in a large cohort. PATIENTS AND METHODS: Patients managed for HNRMS in our institution (1996-2015) were analyzed. The presence of a FOXO1 fusion was required for the classification of ARMS. MYOD1 mutations in SRMS-ScRMS were tested when material available. Univariate and multivariate analyses were performed to evaluate variables related to overall survival (OS). RESULTS: Ninety-nine HNRMS patients (52 males and 47 females, mean of 16years) were included in the study after pathologic re-review. The most common location was parameningeal (PM) (n=64), followed by non-orbital/non-PM (n=25) and orbital (n=10). There were 53 ERMS, 33 fusion-positive ARMS and 13 SRMS-ScRMS [SRMS (8); ScRMS (5)]. The 5-year OS rate for ERMS patients was significantly higher (82%) compared to ARMS (53%) and SRMS-ScRMS (50%) [SRMS (75%); ScRMS (30%)]. Univariate analysis showed that survival was dependent on histology (P=0.012), tumor size >5cm (P<0.001), regional lymph node involvement (P=0.002), metastasis at initial presentation (P<0.001), stage (P<0.001), and recurrence (P=0.002). Multivariate analysis confirmed histologic subtype to be significant (P=0.043). CONCLUSION: Our findings reinforce that HNRMS is a heterogenous disease with ARMS and SRMS-ScRMS having an equally unfavorable outcome.
BACKGROUND: Based on their distinctive histologic and genetic features, the latest WHO classification of soft tissue tumors includes four pathologic variants of rhabdomyosarcoma (RMS): embryonal (ERMS), alveolar (ARMS), spindle cell-sclerosing (SRMS-ScRMS) and pleomorphic RMS. The aim of this study focused on a detailed clinicopathologic and survival analysis of head and neck RMS (HNRMS) using the latest pathologic and molecular criteria reflecting this new subclassification in a large cohort. PATIENTS AND METHODS: Patients managed for HNRMS in our institution (1996-2015) were analyzed. The presence of a FOXO1 fusion was required for the classification of ARMS. MYOD1 mutations in SRMS-ScRMS were tested when material available. Univariate and multivariate analyses were performed to evaluate variables related to overall survival (OS). RESULTS: Ninety-nine HNRMS patients (52 males and 47 females, mean of 16years) were included in the study after pathologic re-review. The most common location was parameningeal (PM) (n=64), followed by non-orbital/non-PM (n=25) and orbital (n=10). There were 53 ERMS, 33 fusion-positive ARMS and 13 SRMS-ScRMS [SRMS (8); ScRMS (5)]. The 5-year OS rate for ERMS patients was significantly higher (82%) compared to ARMS (53%) and SRMS-ScRMS (50%) [SRMS (75%); ScRMS (30%)]. Univariate analysis showed that survival was dependent on histology (P=0.012), tumor size >5cm (P<0.001), regional lymph node involvement (P=0.002), metastasis at initial presentation (P<0.001), stage (P<0.001), and recurrence (P=0.002). Multivariate analysis confirmed histologic subtype to be significant (P=0.043). CONCLUSION: Our findings reinforce that HNRMS is a heterogenous disease with ARMS and SRMS-ScRMS having an equally unfavorable outcome.
Authors: J H M Merks; G L De Salvo; C Bergeron; G Bisogno; A De Paoli; A Ferrari; A Rey; O Oberlin; M C G Stevens; A Kelsey; J Michalski; D S Hawkins; J R Anderson Journal: Ann Oncol Date: 2014-01 Impact factor: 32.976
Authors: Karen W Gripp; Charles I Scott; Linda Nicholson; Donna M McDonald-McGinn; J Daniel Ozeran; Marilyn C Jones; Angela E Lin; Elaine H Zackai Journal: Am J Med Genet Date: 2002-02-15
Authors: Richard Beverly Raney; Jane Meza; James R Anderson; Christopher J Fryer; Sarah S Donaldson; John C Breneman; Thomas J Fitzgerald; Edmund A Gehan; Jeff M Michalski; Jorge A Ortega; Stephen J Qualman; Eric Sandler; Moody D Wharam; Eugene S Wiener; Harold M Maurer; William M Crist Journal: Med Pediatr Oncol Date: 2002-01
Authors: Remco de Bree; Paul van der Valk; Dirk J Kuik; Paul J van Diest; Patricia Doornaert; Jan Buter; Simone E J Eerenstein; Johannes A Langendijk; Isaäc van der Waal; C René Leemans Journal: Oral Oncol Date: 2006-03-10 Impact factor: 5.337
Authors: Rita Alaggio; Lei Zhang; Yun-Shao Sung; Shih-Chiang Huang; Chun-Liang Chen; Gianni Bisogno; Angelica Zin; Narasimhan P Agaram; Michael P LaQuaglia; Leonard H Wexler; Cristina R Antonescu Journal: Am J Surg Pathol Date: 2016-02 Impact factor: 6.394
Authors: Molly Housley Smith; Daniel Atherton; John D Reith; Nadim M Islam; Indraneel Bhattacharyya; Donald M Cohen Journal: Head Neck Pathol Date: 2017-05-02
Authors: Ursula M Jariod-Ferrer; Miguel Angel Trigo-Cebrian; Bianca Pantilie; María V Simon Sanz; Leire Esparza Lasaga; Marina A Gavin-Clavero; Elena Delso-Gil; Javier Martinez-Trufero Journal: J Maxillofac Oral Surg Date: 2020-09-26